Kenneth Waggoner, outgoing PharmaCyte CEO
October 7, 2022 11:41 AM EDTUpdated 11:53 AM
People

Un­der the weight of a 2-year clin­i­cal hold, a biotech’s new board starts com­pa­ny re­view, ousts CEO

Kyle LaHucik

Senior Reporter

Af­ter near­ly 10 years steer­ing the ship at Phar­ma­Cyte Biotech, Ken­neth Wag­goner is out the door of the biotech, as of yes­ter­day, and the for­mer …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

FDA vac­cine chief Pe­ter Marks pledges to stay as long as he's wel­come

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times